Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal.
1. A method of reducing hypercholesteremia in a mammal suffering from hypercholesteremia comprising orally administering to said mammal a homoionic hydrogen ion-exchanged layered phyllosilicate material in an amount effective to reduce hypercholesteremia in said mammal.
2. The method of claim 1 , wherein the layered phyllosilicate material further comprises a pharmaceutically acceptable carrier, diluent or adjuvant.
3. The method of claim 1 , further comprising administering a further cholesterol-reducing agent to said mammal.
4. The method of claim 3 , wherein the cholesterol-reducing agent is selected from the group consisting of a statin-related agent, nicotinic acid, a fibrate, bile acid resins, a cholesterol absorption inhibitor, salicylic acid, a phytosterol, an alginate or a pectin, lecithin and a nutraceutical associated with cholesterol reduction.
5. The method of claim 4 , wherein the statin-related agent is selected from the group consisting of lovastatin, atorvastatin, pravastatin, simvastatin and fluvastatin.
6. The method of claim 4 , wherein the fibrate is selected from the group consisting of bezafibrate, ciprofibrate, clofibrate, gemfibrozil and fenofibrate.
7. The method of claim 4 , wherein the bile acid resin is selected from the group consisting of cholestyramine, colestipol and cholsevelam.
8. The method of claim 4 , wherein the cholesterol absorption inhibitor is ezetimibe.
9. The method of claim 4 , wherein the plant sterol is selected from the group consisting of stigmastanol, sitosterol, sitostanol and policosanol.
10. The method of claim 4 , wherein the nutraceutical associated with cholesterol reduction is selected from the group consisting of epigallocatechin gallate (EGCG), Cholest-Arrest™ (500 mg garlic and 200 mg lecithin), Cholestaway™ (700 mg Calcium carbonate, 170 mg magnesium oxide 50 μg chromium picolinate), CholestOff™ (900 mg of plant sterols/stanols) and Kyolic™ (600 mg aged garlic extract and 380 mg lecithin).
11. The method of claim 3 , further comprising administering a a triglyceride reducing agent to the mammalian subject.
12. The method of claim 3 , wherein the layered phyllosilicate material is administered concurrently with cholesterol-reducing agent.
13. The method of claim 3 , wherein the layered phyllosilicate material is administered at different times than the cholesterol-reducing agent.
14. A method of reducing hypercholesteremia in a mammal suffering from hypercholesteremia comprising orally administering to said mammal a composition consisting of homoionic hydrogen ion-exchanged layered phyllosilicate material and a pharmaceutically acceptable carrier in an amount effective to reduce hypercholesteremia in said mammal.
15. The method of claim 14 , wherein the layered phyllosilicate material has a particle size less than 74 μm.
16. The method of claim 14 , wherein the layered phyllosilicate material comprises exfoliated platelets and/or tactoids of the layered phyllosilicate material.
17. The method of claim 14 , wherein the mammal is human.
18. The method of claim 14 , wherein the mammal is an animal selected from the group consisting of a horse, a cow, sheep, a pig, a llama, an alpaca, a goat, a dog, a cat, a mouse, a rat, a rabbit, a guinea pig and a hamster.